Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.
NP-SLE
Systemic lupus erythematosus
antibodies
cardiovascular risk
magnetic resonance imaging
neuropsychiatric systemic lupus erythematosus
pathogenesis
Journal
Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
pubmed:
12
12
2018
medline:
9
5
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
The effect of serum autoantibodies on the brain of systemic lupus erythematosus (SLE) patients remains unclear. We investigated whether serum autoantibodies, individually and assessed in groups, are associated with specific brain-MRI abnormalities or whether these structural changes are associated with other SLE-related or traditional cardiovascular disease risk factors. All patients underwent brain 3Tesla-MRI. White matter hyperintensities (WMHs), ischemic lesions, inflammatory-like lesions and cerebral atrophy were scored. Serum autoantibodies analyzed included lupus anticoagulant (LAC), anticardiolipine (aCL) IgG and IgM (first 3 also grouped into antiphospholipid autoantibodies (aPL)), anti-dsDNA, anti-SSA, anti-SSB, anti-RNP, and anti-Sm (the latter 5 grouped into SLE-related autoantibodies). Associations were assessed using logistic regression analysis adjusted for potential confounders. Furthermore, a sensitivity analysis including anti-Beta2 glycoprotein-1 antibodies (anti-β2GP1) in the aPL group was performed and the potential modification role of the neuropsychiatric clinical status in the model was assessed. 325 patients (mean age 42 years (SD 14), 89% female) were included. The following MRI-brain abnormalities were found: WMHs (71%), lacunar infarcts (21%), gliosis (11%), micro-hemorrhages (5%), large hemorrhages (2%), inflammatory-like lesions (6%) and atrophy (14%). No associations were found between individual or total SLE-related autoantibodies and inflammatory-like lesions. A higher number of positive aPL was associated with lacunar infarcts (OR 1.37 (95%CI 1.02-1.99) and gliosis (OR 2.15 (1.37-3.37)). LAC was associated with lacunar infarcts in white matter (OR 3.38 (1.32-8.68)) and atrophy (OR 2.49 (1.01-6.15)), and aCL IgG with gliosis (OR 2.71 (1.05-7.02)). Among other variables, SLE patients with hypertension presented a higher chance for WMHs (OR 5.61 (2.52-12.48)) and lacunar infarcts in WM (OR 2.52 (1.10-5.74)) and basal ganglia (OR 8.34 (2.19-31.70)), while cumulative SLE-damage was correlated with lacunar infarcts in WM (OR 1.43 (1.07-1.90)), basal ganglia (OR 1.72 (1.18-2.51)) and cerebellum (OR 1.79 (1.33-2.41)). These associations were confirmed in the sensitivity analysis. Brain abnormalities in SLE represent different underlying pathogenic mechanisms. aPL are associated with ischemic brain changes in SLE, while the presence of SLE-related serum autoantibodies is not related to inflammatory-like lesions. Hypertension and cumulative SLE-damage associate with ischemic MRI-brain changes in SLE, suggesting the importance of accelerated atherosclerosis in this process.
Identifiants
pubmed: 30526327
doi: 10.1177/0961203318816819
pmc: PMC6304692
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-103Références
Nature. 2017 Jun 22;546(7659):539-543
pubmed: 28614301
J Neuroimaging. 2008 Jan;18(1):62-5
pubmed: 18190498
Nat Rev Immunol. 2009 Jun;9(6):449-56
pubmed: 19424277
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
AJNR Am J Neuroradiol. 2014 Jan;35(1):100-5
pubmed: 23886740
Drugs. 2016 Mar;76(4):459-83
pubmed: 26809245
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19854-9
pubmed: 17170137
Scand J Rheumatol. 2005 Sep-Oct;34(5):376-82
pubmed: 16234185
Arthritis Rheum. 2005 Sep;52(9):2783-9
pubmed: 16142703
Blood. 2006 Apr 15;107(8):3229-34
pubmed: 16368889
Semin Arthritis Rheum. 2010 Aug;40(1):32-52
pubmed: 19880162
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Nat Med. 2001 Nov;7(11):1189-93
pubmed: 11689882
Brain. 2002 Apr;125(Pt 4):765-72
pubmed: 11912110
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Ann Rheum Dis. 2016 Nov;75(11):2014-2021
pubmed: 27088255
Nat Rev Rheumatol. 2013 May;9(5):301-10
pubmed: 23229448
J Rheumatol. 2008 Dec;35(12):2348-54
pubmed: 18793003
Lancet. 1995 Dec 23-30;346(8991-8992):1647-53
pubmed: 8551820
Ann Rheum Dis. 2011 Oct;70(10):1726-32
pubmed: 21893582
Lancet Neurol. 2009 Nov;8(11):998-1005
pubmed: 19783216
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
Stroke. 2016 Nov;47(11):2722-2728
pubmed: 27703087
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2246-2251
pubmed: 27609370
J Autoimmun. 2007 Mar-May;28(2-3):160-4
pubmed: 17419007
J Neurol. 2017 Jul;264(7):1474-1481
pubmed: 28653212
Clin Rheumatol. 1994 Dec;13(4):615-8
pubmed: 7697965
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Lupus. 1998;7(2):124-31
pubmed: 9541097
Arthritis Rheum. 2011 Mar;63(3):722-32
pubmed: 21360502
Lupus. 2016 Jul;25(8):878-88
pubmed: 27252265
Rheumatology (Oxford). 2017 Oct 1;56(10):1676-1683
pubmed: 28339952
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
J Thromb Haemost. 2015 Sep;13(9):1568-75
pubmed: 26178535
J Neurol. 2003 Nov;250(11):1348-54
pubmed: 14648152
Arthritis Rheum. 2007 Sep;56(9):3112-24
pubmed: 17763410
Autoimmun Rev. 2015 Feb;14(2):153-9
pubmed: 25461835
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Nat Immunol. 2007 May;8(5):487-96
pubmed: 17417641
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
J Rheumatol. 2012 Nov;39(11):2118-26
pubmed: 22984275
J Rheumatol. 2000 Feb;27(2):373-6
pubmed: 10685799
Eur Neurol. 1996;36(5):268-72
pubmed: 8864706
Autoimmun Rev. 2015 Jun;14(6):510-6
pubmed: 25617815
Rheumatology (Oxford). 2017 Jan;56(1):77-86
pubmed: 28028157
Arthritis Rheumatol. 2016 Aug;68(8):1945-54
pubmed: 26894522
Ann Neurol. 2008 Dec;64(6):635-43
pubmed: 19107986